(Gaithersburg, MD), entered into a research collaboration with the Cordis Cardiology Division of Cordis Corporation, a Johnson & Johnson (New Brunswick, NJ) company, to study the clinical benefit of BIOBYPASS in a procedure involving guided delivery of the angiogenic agent directly into targeted regions of the heart in patients with severe coronary artery disease using the Cordis NOGASTAR Mapping Catheter and MYOSTAR Injection Catheter.
"We are enthusiastic about our collaboration with Cordis Corporation, a recognized leader in the field of cardiovascular devices, as it provides a solid platform to advance both BIOBYPASS and the NOGASTAR and MYOSTAR catheters into the next stage of clinical development," said William Enright, GenVec's Director of Corporate Development.
The purpose of the collaboration is to conduct a randomized, double-blind, placebo controlled study of GenVec's cardiovascular product candidate, BIOBYPASS. Clinical benefit will be assessed in this multi-center study, which will be conducted in Europe and is expected to enroll up to 125 patients with heart disease.
GenVec has already received $54 million based on developments with Biobypass, its blood vessel growth stimulator and gene therapy drug designed to bypass clogged arteries and prevent coronary artery disease and peripheral vascular disease.
It could now receive an additional $47 million in milestone and equity payments as development of Biobypass progresses.
The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as TNFerade for cancer, BIOBYPASS
for coronary artery disease, and AdPEDF for macular degeneration.
"Many of these patients are too ill for bypass surgery, and biobypass
or TMLR [transmyocardial laser revascularization] is just about the only therapy left," says Summers.
The company combines its patented gene transfer technologies with proprietary therapeutic genes to create product candidates, such as BioBypass
angiogen for cardiovascular disease, TNFerade for cancer and AdPEDF for macular degeneration and diabetic retinopathy.
GenVec's lead cardiovascular product candidate is BioBypass
angiogen, which is in late-stage randomized Phase II studies in collaboration with Pfizer, Inc.
In addition to GenVec's PEDF discovery program for the prevention of blindness, the company is developing BIOBYPASS angiogen, a novel gene-based therapy that induces the formation of new blood vessels in the heart and other areas affected by inadequate blood flow.
The company combines its patented gene transfer technologies with proprietary the>rapeutic genes to create product candidates, such as BIOBYPASS angiogen and GENSTENT biologic that address medical needs in the areas of cardiovascular disease, TNFerade biologic for oncology and the PEDF program for ophthalmology.
This patent adds an additional layer of proprietary protection for our growing product portfolio, that includes our therapeutic angiogenesis product candidate, BIOBYPASS
angiogen, which is now in Phase II clinical studies for the treatment of coronary artery disease."